23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Saniona takes fast-acting depression drug into clinical trials

The Danish-Swedish research company Saniona has received clearance to initiate clinical trials in the US with its drug candidate SAN2465 for major depressive disorder (MDD).
Advertisement

The US Food and Drug Administration (FDA) has approved Saniona's Investigational New Drug application. This allows the company to launch a phase 1 study to assess the safety, tolerability and pharmacokinetics of SAN2465 in healthy volunteers.

Using cognitive tests and EEG, the researchers will also study how the substance affects brain function and identify suitable doses for future patient studies.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.074|